Acute Spinal Cord Injury

@article{Witiw2015AcuteSC,
  title={Acute Spinal Cord Injury},
  author={Christopher D. Witiw and Michael G. Fehlings},
  journal={Journal of Spinal Disorders and Techniques},
  year={2015},
  volume={28},
  pages={202–210}
}
Our understanding of the pathophysiological processes that comprise the early secondary phases of spinal cord injury such as spinal cord ischemia, cellular excitotoxicity, ionic dysregulation, and free-radical mediated peroxidation is far greater now than ever before, thanks to substantial laboratory research efforts. These discoveries are now being translated into the clinical realm and have led to targeted upfront medical management with a focus on tissue oxygenation and perfusion and include… Expand
Fibroblast growth factors in the management of spinal cord injury
TLDR
This review focuses on the therapeutic capacity and pitfalls of the FGF family and its clinical application for treating SCI, including the signalling component ofThe FGF pathway and the role in the central nervous system, the pathophysiology of SCI and the targets for FGF treatment. Expand
Biomarkers in Spinal Cord Injury: Prognostic Insights and Future Potentials
TLDR
An extensive literature review was performed covering literature, published in English, until February 2018 using the Medline/PubMed database, and observed two methods that may lead to the appearance of biomarkers for SCI. Expand
Acute Spinal Cord Injury: A Systematic Review Investigating miRNA Families Involved
TLDR
Investigating the pathology and degree of clinical diagnosis and treatment strategies, the animal models that have allowed us to better understand this entity and the role of new diagnostic and prognostic tools such as miRNA could improve the ability to manage this pathological entity. Expand
Differential Neuroproteomic and Systems Biology Analysis of Spinal Cord Injury*
TLDR
Systems biology approach was utilized to determine the critical biochemical pathways and interactome in the pathogenesis of SCI and candidate biomarkers identified can be used to correlate with disease progression or to identify potential SCI therapeutic targets. Expand
Spinal cord trauma: pathophysiology, classification of spinal cord injury syndromes, treatment principles and controversies
TLDR
An overview of all aspects of early and long term spinal cord injury management focuses on the patho-physiological mechanisms of the acute injury phase and the different clinical types of cord injury syndromes. Expand
Cell therapy for the treatment of spinal cord injury with focus on stem cells: A review
TLDR
A number of different cell therapies have been evaluated in both pre-clinical and clinical trials and here a review of these studies that evaluated the following types of cell therapies discusses the advantages and disadvantages of each cell type and their specific role in functional improvement. Expand
Neuroprotective Effects of Milrinone on Experimental Acute Spinal Cord Injury: Rat Model.
TLDR
Milrinone could reduce apoptosis, increase anti-inflammatory and anti-oxidative mediators, thus playing a protective role in secondary nerve injury after SCI in rats, and Neurological examination scores were significantly better in milrinone treated group compared to groups 2 and 3. Expand
Ultrasound in Traumatic Spinal Cord Injury: A Wide-Open Field.
TLDR
This review suggests that studies that evaluate the benefits and risks of ultrasound in SCI are severely lacking and the understanding of the technology's potential impact remains poorly understood. Expand
Improving the therapeutic efficacy of neural progenitor cell transplantation following spinal cord injury
TLDR
The authors discuss the challenges of NPC transplantation with respect to different populations of NPCs of glial and neuronal lineages, the timing of treatment relative to acute and chronic injury, and the progress in ongoing clinical trials. Expand
The current role of steroids in acute spinal cord injury.
TLDR
This review presents the pathophysiology of ASCI and the laboratory and clinical findings on the use of MP and concludes that high-dose MP cannot be recommended as a standard of care, but it remains an option until supplanted by future evidence-based therapies. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 49 REFERENCES
Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon.
TLDR
Cell-based strategies including using neural stem cells to remyelinate spared axons are an attractive emerging approach and Regenerative approaches to block inhibitory signals including Nogo and the Rho-Rho-associated kinase pathways have shown promise and are in early stages of clinical evaluation. Expand
Cardiovascular complications after acute spinal cord injury: pathophysiology, diagnosis, and management.
TLDR
The authors summarize the neural regulation of the cardiovascular system as well as the pathophysiology, diagnosis, and management of major cardiovascular complications that can occur following acute (up to 30 days) traumatic SCI. Expand
Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury.
TLDR
The minocycline regimen established in this study proved feasible, safe and was associated with a tendency towards improvement across several outcome measures, which are encouraging and warrant further investigation in a multi-centre phase III trial. Expand
Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury
TLDR
The results support reports that modulating apoptosis, caspases, and microglia provide promising therapeutic targets for prevention and/or limiting the degree of functional loss after CNS trauma and minocycline, and more potent chemically synthesized tetracyclines, may find a place in the therapeutic arsenal to promote recovery early after SCI in humans. Expand
A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury.
TLDR
The observed motor recovery in this open-label trial suggests that BA-210 may increase neurological recovery after complete SCI, and further clinical trials with Cethrin in SCI patients are planned, to establish evidence of efficacy. Expand
Magnesium chloride in a polyethylene glycol formulation as a neuroprotective therapy for acute spinal cord injury: preclinical refinement and optimization.
TLDR
An "optimized" regimen of MgCl(2) within PEG conferred greater tissue neuroprotection and improved locomotor recovery compared to methylprednisolone, and a 4 hour time window of histologic and behavioral efficacy was established. Expand
Timing of decompressive surgery of spinal cord after traumatic spinal cord injury: an evidence-based examination of pre-clinical and clinical studies.
TLDR
There is evidence to suggest that early surgical intervention is safe and feasible and that it can improve clinical and neurological outcomes and reduce health care costs. Expand
Basic Fibroblast Growth Factor (bFGF) Enhances Functional Recovery Following Severe Spinal Cord Injury to the Rat
TLDR
In summary, intrathecal infusion of bFGF following severe SCI significantly restores gross hindlimb motor function that is not correlated with significant tissue sparing, indicating that yet undefined mechanisms contribute to the enhanced functional recovery following bF GF treatment. Expand
Early versus Delayed Decompression for Traumatic Cervical Spinal Cord Injury: Results of the Surgical Timing in Acute Spinal Cord Injury Study (STASCIS)
TLDR
Decompression prior to 24 hours after SCI can be performed safely and is associated with improved neurologic outcome, defined as at least a 2 grade AIS improvement at 6 months follow-up. Expand
Pharmacological therapy for acute spinal cord injury.
TLDR
Clinicians considering MP therapy should bear in mind that the drug is not Food and Drug Administration approved for this application, and there is no Class I or Class II medical evidence supporting the clinical benefit of MP in the treatment of acute SCI. Expand
...
1
2
3
4
5
...